Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Airway Remodeling D056151 3 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Stroke D020521 32 associated lipids
Latex Hypersensitivity D020315 1 associated lipids
Intracranial Hemorrhage, Hypertensive D020299 1 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Venous Thrombosis D020246 11 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Carotid Artery Injuries D020212 8 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Basal Ganglia Hemorrhage D020145 1 associated lipids
Thrombophilia D019851 6 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Atrial Premature Complexes D018880 1 associated lipids
Sepsis D018805 11 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Osteoblastoma D018215 1 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
beta-Thalassemia D017086 5 associated lipids
Carotid Stenosis D016893 15 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Yang Deficiency D016711 3 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Reperfusion Injury D015427 65 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Wounds and Injuries D014947 20 associated lipids
Weil Disease D014895 2 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Varicose Veins D014648 7 associated lipids
Uveitis D014605 14 associated lipids
Uterine Neoplasms D014594 18 associated lipids
Uremia D014511 33 associated lipids
Ulcer D014456 16 associated lipids
Tooth, Impacted D014095 9 associated lipids
Thrombosis D013927 49 associated lipids
Thromboembolism D013923 6 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombocythemia, Essential D013920 9 associated lipids
Thromboangiitis Obliterans D013919 4 associated lipids
Thrombasthenia D013915 4 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Tachycardia, Supraventricular D013617 3 associated lipids
Tachycardia, Paroxysmal D013614 2 associated lipids
Tachycardia D013610 7 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Strongyle Infections, Equine D013319 1 associated lipids
Streptococcal Infections D013290 4 associated lipids
Stomach Volvulus D013277 1 associated lipids
Stomach Ulcer D013276 75 associated lipids
Gastric Dilatation D013271 1 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Sneezing D012912 6 associated lipids
Shock, Septic D012772 11 associated lipids
Shock D012769 11 associated lipids
Seizures D012640 87 associated lipids
Sclerosis D012598 5 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Salmonella Infections, Animal D012481 9 associated lipids
Rhinitis D012220 10 associated lipids
Retinal Vein Occlusion D012170 2 associated lipids
Retinal Diseases D012164 4 associated lipids
Retinal Detachment D012163 10 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiratory Hypersensitivity D012130 18 associated lipids
Respiratory Distress Syndrome, Adult D012128 15 associated lipids
Respiration Disorders D012120 5 associated lipids
Renal Artery Obstruction D012078 8 associated lipids
Raynaud Disease D011928 7 associated lipids
Radiculopathy D011843 1 associated lipids
Radiation Injuries, Experimental D011833 11 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Purpura, Schoenlein-Henoch D011695 5 associated lipids
Pulmonary Heart Disease D011660 2 associated lipids
Pulmonary Embolism D011655 5 associated lipids
Pulmonary Edema D011654 23 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Teraoka S et al. Multicenter trial of the therapeutic effect of a newly developed antiplatelet agent, satigrel, on biopsy-proven chronic rejection after kidney transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9122990
Ishine N et al. Hemodynamic analysis of post-reperfusion syndrome and the effect of preventing this syndrome using thromboxane A2 synthetase inhibitor (OKY-046) in swine liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123045
Suehiro T et al. Value of caval effluent in predicting early graft function after orthotopic liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123086
Yagi T et al. Hepatropic soluble vitamin E derivative EPC-K1 prevents warm ischemia/reperfusion injury of non-heart-beating donor liver transplantation in pigs. 1997 Feb-Mar Transplant. Proc. pmid:9123352
Hashimoto T et al. Experimental study on the relationship between prostaglandin production and acute pancreatic rejection. 1989 Transplant. Proc. pmid:2495617
Jorkasky DK et al. The effects of cyclosporine on human platelet aggregation and thromboxane release. 1989 Transplant. Proc. pmid:2705264
López-Boado MA et al. Free radical ablation prevents ischemic injury after long periods of cold storage in rat pancreas transplantation. 1990 Transplant. Proc. pmid:2219357
Alcaraz A et al. Experimental kidney transplantation in pigs from non-heart-beating donors: evaluation of vasoactive substances and renal artery flow. 2001 Transplant. Proc. pmid:11543815
Anderson CB et al. Thromboxane-B2 and renovascular resistance during hypothermic pulsatile perfusion. 1981 Transplant. Proc. pmid:7268892
Shimizu Y et al. Nafamostat mesilate prevents warm ischemia-reperfusion injury in canine pancreas autotransplantation. 1995 Transplant. Proc. pmid:8539906
Odor-Morales A et al. In vivo thromboxane production by different organs in the rat: its implication in organ transplant failure. 1987 Transplant. Proc. pmid:3617213
Kanji VK et al. Vitamin E suppresses cyclosporine A-induced increase in the urinary excretion of arachidonic acid metabolites including F2-isoprostanes in the rat model. 1999 Transplant. Proc. pmid:10331052
García-Valdecasas JC et al. Prostaglandin metabolism and hemodynamic alterations during human liver transplantation. 1993 Transplant. Proc. pmid:8470202
Uchiyama M et al. Comparison between nonpulsatile and pulsatile machine perfusion preservation in liver transplantation from non-heart-beating donors. 2001 Feb-Mar Transplant. Proc. pmid:11267136
Hoballah JJ et al. Lazaroid U74389G attenuates skeletal muscle reperfusion injury in a canine model. 1995 Transplant. Proc. pmid:7482936
Kasahara M et al. Effect of FK3311 on ischemia-reperfusion injury in canine pulmonary models. 2000 Transplant. Proc. pmid:11120230
Quarto Di Palo F et al. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. 1991 Transplant. Proc. pmid:1989347
Foegh ML et al. Thromboxane and inflammatory cell infiltration of the allograft of renal transplant patients. 1987 Transplant. Proc. pmid:3313875
Santillan-Doherty P et al. Urinary thromboxane B2 excretion during acute rejection in cyclosporine-treated experimental lung allotransplantation. 1992 Transplant. Proc. pmid:1412957
Norio K et al. Eicosanoids and delayed graft function in human renal transplantation. 2001 Transplant. Proc. pmid:11406239
Saumweber DM et al. The involvement of platelet-activating factor in hyperacute xenogeneic rejection and its modulation by the PAF-antagonist WEB 2086BS. 1991 Transplant. Proc. pmid:1990613
Su CL et al. Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats. 2012 Transplant. Proc. pmid:22564588
Pestana M et al. Kidney graft-infiltrating cells synthesize significantly higher amounts of prostaglandin E2 pre and during acute rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083119
van den Dorpel MA et al. Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. 1999 Feb-Mar Transplant. Proc. pmid:10083130
WÅ‚odarczyk Z et al. Effects of pentoxifylline treatment on delayed graft function in cadaveric kidney recipients. 2000 Transplant. Proc. pmid:10995988
Schultze G et al. Effect of cyclosporine on the generation of prostanoids by cultured peripheral lymphocytes. 1984 Transplant. Proc. pmid:6592863
Nakache R et al. Pancreatic juice immunoreactive thromboxane B2 in pancreas allograft rejection. 1990 Transplant. Proc. pmid:1691546
Odor-Morales A et al. Urinary amylase, urinary insulin, or urinary thromboxane: which is the best predictor of pancreatic allograft rejection in the dog? 1990 Transplant. Proc. pmid:1691549
Urade M et al. Changes of thromboxane B2 level in experimental orthotopic liver transplantation in swines--the effect of warm ischemia and thromboxane A2 synthetase inhibition. 1992 Transplant. Proc. pmid:1496677
Oikawa K et al. Elimination of Kupffer cells suppresses activation of nuclear factor kappa B and production of cytokines and eicosanoids in non-heart-beating donors. 2001 Feb-Mar Transplant. Proc. pmid:11267090
Lim LK et al. Fine needle aspiration biopsy, serum beta 2-microglobulin, and urine thromboxane in renal allografts. 1989 Transplant. Proc. pmid:2669249
Odor-Morales A et al. Urinary thromboxane B2 as indicator of pancreatic allograft rejection in nonimmunosuppressed dogs. 1989 Transplant. Proc. pmid:2669272
Santillan-Doherty P et al. Thromboxane B2 and lung transplantation: correlation of rejection with levels detected in bronchoalveolar lavage. 1989 Transplant. Proc. pmid:2669273
Zhao Y et al. Feasibility of serial fine needle aspiration biopsies to monitor dog single lung allografts. 1989 Transplant. Proc. pmid:2669274
Foegh ML et al. Urine thromboxane as an immunologic monitor in kidney transplant patients. 1984 Transplant. Proc. pmid:6390872
Saumweber DM et al. Studies on xenograft rejection: the role of leukocytes and prostaglandins and their modulation by the hetrazepine WEB 2086BS. 1992 Transplant. Proc. pmid:1566436
Pratschke J et al. Allogeneic heart transplantation following xenografting. 1992 Transplant. Proc. pmid:1566482
Sinzinger H et al. Platelet-derived growth factor and prostacyclin in kidney transplant rejection. 1987 Transplant. Proc. pmid:3303560
Elzinga L et al. Fish oil vehicle for cyclosporine lowers renal thromboxanes and reduces experimental nephrotoxicity. 1987 Transplant. Proc. pmid:3824502
Anderson C et al. Thromboxane synthesis inhibition and renal allograft function. 1989 Transplant. Proc. pmid:2650085
Pepino P et al. LTC4, thromboxane B2 and 6-keto PGF1 in syngeneic and allogenic heterotopic cardiac transplant in rats. 1989 Transplant. Proc. pmid:2650170
Seelos R et al. Prostaglandin synthesis and survival after orthotopic liver transplantation in pigs. 1991 Transplant. Proc. pmid:1926413
Iyobe T et al. Changes in prostaglandin levels in experimental liver transplantation in rats. 1994 Transplant. Proc. pmid:8066723
Kagawa K et al. Prolongation of rat cardiac allograft survival with arachidonic acid metabolism inhibitor. 1987 Transplant. Proc. pmid:3103286
Foegh ML et al. Differential effect of CGS 13080, a thromboxane synthase inhibitor, in suppressing serum and urine immunoreactive thromboxane B2 in kidney transplant patients. 1988 Transplant. Proc. pmid:3279631
Pittet JF et al. Protective effect of indomethacin in the development of the postreperfusion syndrome during liver transplantation in pigs. 1991 Transplant. Proc. pmid:1871874
Quereda C et al. Urinary thromboxane B2 and cyclic AMP in cyclosporine-A-treated kidney transplantation. 1994 Transplant. Proc. pmid:7940810
Fukuoka T et al. Platelet-activating factor as a vasodepressive mediator of liver ischemia. 1993 Transplant. Proc. pmid:8266523
Lim LK et al. Effect of the 5-lipoxygenase inhibitors EP 10045 and EP 10161 on cardiac graft cellular infiltrate and thromboxane formation. 1988 Transplant. Proc. pmid:3284052
Lim LK et al. Correlation of renal inflammatory cell infiltrate with thromboxane. 1988 Transplant. Proc. pmid:3284053
Ohsaki S et al. Effect of prostaglandin E1 on graft function of kidneys from living related donors. 1992 Transpl. Int. pmid:14621746
Schütz A et al. Allogeneic heart transplantation following xenogeneic bridging. 1992 Transpl. Int. pmid:14621808
Yamada K et al. New morphological changes induced by FK506 in a short period in the rat kidney and the effect of superoxide dismutase and OKY-046 on THEM: the relationship of FK506 nephrotoxicity to lipid peroxidation and change in production of thromboxane A2 in the kidney. 1992 Transpl. Int. pmid:14621878
Mennander A et al. Chronic rejection of rat aortic allografts: effect of inhibition of the thromboxane cascade. 1992 Transpl. Int. pmid:14621882
Gianello P et al. Measurement of the vasoconstrictive substances endothelin, angiotensin II, and thromboxane B2 in cold storage solution can reveal previous renal ischemic insults. 1994 Transpl. Int. pmid:8117396
Torras J et al. Renal protective effect of liposomed superoxide dismutase in an experimental warm ischemia model. 1994 Transpl. Int. pmid:11271283
Yokoyama I et al. Liberation of vasoactive substances and its prevention with thromboxane A2 synthase inhibitor in pig liver transplantation. 1996 Transpl. Int. pmid:8748415
van Marwijk Kooy M et al. Filtration. A method to prepare white cell-poor platelet concentrates with optimal preservation of platelet viability. 1990 Transfusion pmid:2296787
Valeri CR et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. 2001 Transfusion pmid:11493727
Böck M et al. Storage of single-donor platelet concentrates: metabolic and functional changes. 1993 Transfusion pmid:8480351
Hansen TN and Brockbank KG Increased platelet aggregation due to chilling to 20 degrees C is not related to increased sensitivity to agonists. 1997 Transfusion pmid:9225932
van Prooijen HC et al. Differences in the susceptibility of platelets to freezing damage in relation to size. 1989 Jul-Aug Transfusion pmid:2526399
Stuart MJ The effect of irradiation on platelet arachidonic acid metabolism. 1983 Mar-Apr Transfusion pmid:6404019
Wallvik J et al. The effect of different agitation modes on platelet metabolism, thromboxane formation, and alpha-granular release during platelet storage. 1990 Transfusion pmid:2119532
Menitove JE et al. Use of PGE1 for preparation of platelet concentrates. 1986 Jul-Aug Transfusion pmid:2941906
Menitove JE et al. Use of prostacyclin to inhibit activation of platelets during preparation of platelet concentrates. 1984 Nov-Dec Transfusion pmid:6390814
Valeri CR et al. Circulation and hemostatic function of autologous fresh, liquid-preserved, and cryopreserved baboon platelets transfused to correct an aspirin-induced thrombocytopathy. 2002 Transfusion pmid:12430680
Boeri N et al. Influence of a 12-hour, 22 degrees C holding period for buffy coats on the preparation of platelet concentrates stored in plasma. 1994 Transfusion pmid:7940660
Güllner HG et al. Correction of increased prostacyclin production in Bartter's syndrome by indomethacin. 1980 Trans. Assoc. Am. Physicians pmid:7018063
Di Minno G et al. In vivo platelet activation in homozygous cystathionine beta-synthase deficiency: a probucol-sensitive phenomenon. 1992 Trans. Assoc. Am. Physicians pmid:1308991
Tobian L et al. Prostaglandin alterations in barely hypertensive Dahl S rats. 1985 Trans. Assoc. Am. Physicians pmid:3842205
Bito LZ Prostaglandins and other eicosanoids: their ocular transport, pharmacokinetics, and therapeutic effects. 1986 Trans Ophthalmol Soc U K pmid:3541303
Zapol WM et al. Plasma thromboxane and prostacyclin metabolites in sheep partial cardiopulmonary bypass. 1980 Trans Am Soc Artif Intern Organs pmid:7018060
Westenfelder C et al. Renal function in calves with total artificial hearts. 1985 Trans Am Soc Artif Intern Organs pmid:3837477
Wonders TR et al. Reduced plasma thromboxane elevation during partial cardiopulmonary bypass in thrombocytopenic sheep. 1981 Trans Am Soc Artif Intern Organs pmid:7331082
Song YM et al. Effects of scorpion venom bioactive polypolypeptides on platelet aggregation and thrombosis and plasma 6-keto-PG F1alpha and TXB2 in rabbits and rats. 2005 Toxicon pmid:15975616
Huang HC Release of slow reacting substance from the guinea-pig lung by phospholipases A2 of Vipera russelli snake venom. 1984 Toxicon pmid:6206608
Al-Hassan JM et al. Vasoconstrictor components in the Arabian Gulf catfish (Arius thalassinus, Ruppell) proteinaceous skin secretion. 1986 Toxicon pmid:3824400
Chan CP et al. Inhibition of cyclooxygenase activity, platelet aggregation and thromboxane B2 production by two environmental toxicants: m- and o-cresol. 2005 Toxicology pmid:15664436
Mayer AM et al. Cyanobacterial Microcystis aeruginosa lipopolysaccharide elicits release of superoxide anion, thromboxane Bâ‚‚, cytokines, chemokines, and matrix metalloproteinase-9 by rat microglia. 2011 Toxicol. Sci. pmid:21362633
Mayer AM et al. Classical and Alternative Activation of Cyanobacterium Oscillatoria sp. Lipopolysaccharide-Treated Rat Microglia in vitro. 2016 Toxicol. Sci. pmid:26609141
Ren R et al. Protective effects of Danshensu on liver injury induced by omethoate in rats. 2010 Toxicol. Mech. Methods pmid:20843270
Leung LK and Glauert HP Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate. 1996 Toxicol. Lett. pmid:8644126
Ferrari D et al. Cyanidin-3-O-glucoside inhibits NF-kB signalling in intestinal epithelial cells exposed to TNF-α and exerts protective effects via Nrf2 pathway activation. 2016 Toxicol. Lett. pmid:27793764
McKinnon KP et al. In vitro ozone exposure increases release of arachidonic acid products from a human bronchial epithelial cell line. 1993 Toxicol. Appl. Pharmacol. pmid:8442000
Carpenter LJ and Roth RA Involvement of thromboxane in injury to isolated rat lungs perfused with phorbol myristate acetate in the presence and absence of neutrophils. 1987 Toxicol. Appl. Pharmacol. pmid:3672516
Sahota T et al. Model-based analysis of thromboxane Bâ‚‚ and prostaglandin Eâ‚‚ as biomarkers in the safety evaluation of naproxen. 2014 Toxicol. Appl. Pharmacol. pmid:24667227
Eisenmann CJ and Miller RK The effect of selenium compounds (selenite, selenate, ebselen) on the production of thromboxane and prostacyclin by the human term placenta in vitro. 1995 Toxicol. Appl. Pharmacol. pmid:7482536
Fujimoto Y et al. Effects of endocrine disruptors on arachidonic acid metabolism in rabbit platelets. 2003 Toxicol. Appl. Pharmacol. pmid:12781627
Ganey PE and Roth RA 5-Hydroxytryptamine and thromboxane in platelets from rats treated with monocrotaline pyrrole. 1987 Toxicol. Appl. Pharmacol. pmid:3564035
Miller PD et al. Effect of ozone exposure on lung functions and plasma prostaglandin and thromboxane concentrations in guinea pigs. 1987 Toxicol. Appl. Pharmacol. pmid:3470978
Yarom R et al. The effect of T-2 toxin on human platelets. 1984 Toxicol. Appl. Pharmacol. pmid:6710522
Santostefano MJ et al. Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. 2012 Toxicol Pathol pmid:22552394
Nakazawa I et al. Some features of the metastatic cancer cells in prostaglandin production. 1989 Tohoku J. Exp. Med. pmid:2510366
Watanabe J et al. Effect of vitamin E on platelet aggregation in diabetes mellitus. 1984 Tohoku J. Exp. Med. pmid:6474447
Watanabe J et al. Effect of prostaglandin synthetase inhibitors on platelet aggregation and thromboxane production in diabetes mellitus. 1984 Tohoku J. Exp. Med. pmid:6515648
Nakazawa I et al. Some features in prostaglandin synthesis of the cancer cells which metastasized into liver from intestinal cancer lesions. 1993 Tohoku J. Exp. Med. pmid:8266326
Tomita Y et al. Leukotrienes and thromboxane B2 stimulate normal human melanocytes in vitro: possible inducers of postinflammatory pigmentation. 1988 Tohoku J. Exp. Med. pmid:3252558
Perkett EA et al. Lymphocyte and granulocyte migration across the endothelial layer of bovine pulmonary artery intimal explants towards lymphocyte conditioned medium. 1986 Tissue Cell pmid:3810636
Wallis RB Mechanisms of action of sulphinpyrazone. 1983 Thromb. Res. Suppl. pmid:6415857